… The EGFR monoclonal antibody cetuximab is generally used in combination with radiation
in HPV-negative HNSCC where comorbidities prevent the use of cytotoxic chemotherapy. …

… However, Palmer et al. found that radiotherapy + cetuximab was well tolerated and resulted
… with radiotherapy + cetuximab for cutaneous squamous cell cancer of the head and neck in …

Background The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal
growth factor receptor (anti-EGFR) antibody tomuzotuximab against cetuximab …

… Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment
of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. …

… Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is
currently an incurable disease. To improve treatment strategies, combinations of cetuximab plus …

… with weekly cetuximab and … cetuximab previously had shorter PFS and OS than those who
had not. Conclusion: Cmab-PTX may be considered as a treatment option in head and neck …

… There is limited evidence supporting the use of taxane‐based chemotherapy combined
with cetuximab to treat recurrent/metastatic head and neck squamous cell carcinoma (R/M …

… Cetuximab represents a potential option for those ineligible for cisplatin or, until recently,
an … carcinoma (OPSCC). Our objective was to define the toxicity and efficacy of cetuximab-…

… Cetuximab has been widely used in the clinical treatment of head and neck squamous
cell carcinoma (… 1 (lncRNA PVT1) is correlated with cetuximab resistance remains unclear. …

… head and neck squamous cell carcinomas (HNSCCs) express epidermal growth factor receptor
(EGFR), and its presence is associated with poor outcomes. Cetuximab, … -dependent cell-…